Abstract
Paralleling breast conservation therapy for invasive breast cancers, treatment for ductal carcinoma in situ (DCIS) has followed the treatment paradigm of surgery and postoperative radiotherapy. Randomized studies evaluating the need for radiation therapy following lumpectomy in patients with DCIS from both the NSABP (B-17) and the EORTC (10853) demonstrated a local control benefit that was homogeneous across all treatment groups. In an era of medicine driven by characterization of tumors into molecular subsets and increasingly focused on individualizing treatment, this “one size fits all” mentality has been challenged. With respect to invasive disease, it has become clear that while prospective randomized studies continue to show a reduction in local recurrence with the addition of postoperative radiation therapy, the magnitude of benefit varies among subsets of patients. The variability in the magnitude of benefit from postoperative radiotherapy was additionally demonstrated in a study showing further reduction in recurrence risk with the addition of a boost following whole breast treatment for invasive disease. In DCIS large randomized trials evaluating the additional efficacy of a boost and which subsets of patients would benefit the most, are lacking. While an international trial evaluating the benefit of a boost in patients with DCIS continues to accrue, the question of the risk:benefit ratio with the use of a boost and whom it will best serve remains unanswered.
Keywords: DCIS, breast cancer, radiation therapy, radiation boost, review
Current Cancer Therapy Reviews
Title: The Importance and Evolution of Radiation Dose in DCIS
Volume: 6 Issue: 3
Author(s): Kimberly S. Keene and Jennifer De Los Santos
Affiliation:
Keywords: DCIS, breast cancer, radiation therapy, radiation boost, review
Abstract: Paralleling breast conservation therapy for invasive breast cancers, treatment for ductal carcinoma in situ (DCIS) has followed the treatment paradigm of surgery and postoperative radiotherapy. Randomized studies evaluating the need for radiation therapy following lumpectomy in patients with DCIS from both the NSABP (B-17) and the EORTC (10853) demonstrated a local control benefit that was homogeneous across all treatment groups. In an era of medicine driven by characterization of tumors into molecular subsets and increasingly focused on individualizing treatment, this “one size fits all” mentality has been challenged. With respect to invasive disease, it has become clear that while prospective randomized studies continue to show a reduction in local recurrence with the addition of postoperative radiation therapy, the magnitude of benefit varies among subsets of patients. The variability in the magnitude of benefit from postoperative radiotherapy was additionally demonstrated in a study showing further reduction in recurrence risk with the addition of a boost following whole breast treatment for invasive disease. In DCIS large randomized trials evaluating the additional efficacy of a boost and which subsets of patients would benefit the most, are lacking. While an international trial evaluating the benefit of a boost in patients with DCIS continues to accrue, the question of the risk:benefit ratio with the use of a boost and whom it will best serve remains unanswered.
Export Options
About this article
Cite this article as:
S. Keene Kimberly and De Los Santos Jennifer, The Importance and Evolution of Radiation Dose in DCIS, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698160
DOI https://dx.doi.org/10.2174/157339410791698160 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure Guided Molecular Docking Assisted Alignment Dependent 3DQSAR Study on Steroidal Aromatase Inhibitors (SAIs) as Anti-breast Cancer Agents
Letters in Drug Design & Discovery A Review on Designing Poly (Lactic-co-glycolic Acid) Nanoparticles as Drug Delivery Systems
Pharmaceutical Nanotechnology Role of the Renin-Angiotensin System in Gynecologic Cancers
Current Cancer Drug Targets Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy
Current Topics in Medicinal Chemistry pH-Sensitive PEGylated Liposomes Functionalized With a Fibronectin-Mimetic Peptide Show Enhanced Intracellular Delivery to Colon Cancer Cells
Current Pharmaceutical Biotechnology The Effects of 1,3,5-trisubstituted Indole Derivatives on Cell Growth, Apoptosis and MMP-2/9 mRNA Expression of MCF-7 Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Engineered Peptides for Applications in Cancer-Targeted Drug Delivery and Tumor Detection
Mini-Reviews in Medicinal Chemistry Anatomical, Biochemical and Physiological Considerations of the Colon in Design and Development of Novel Drug Delivery Systems
Current Drug Delivery Meet Our Editorial Board Member
Current Cancer Drug Targets Evolution of the Strategies for Screening and Identifying Human Tumor Antigens
Current Protein & Peptide Science Anticancer Advances of Matrine and Its Derivatives
Current Pharmaceutical Design The Role of Radiopharmaceuticals in Amiodarone-Induced Thyroid Pathology
Current Radiopharmaceuticals Preface
Current Pharmaceutical Design Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins
Current Gene Therapy Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Current Insights into the Role of HIF-1 in Cutaneous Wound Healing
Current Molecular Medicine Apoptotic Effects of Some Tetrahydronaphthalene Derivatives on K562 Human Chronic Myelogenous Leukemia Cell Line
Anti-Cancer Agents in Medicinal Chemistry